4 Health Problems Men Ignore (And Why Telehealth Fixes Them)

Bottom line: Erectile dysfunction, low testosterone, and male-pattern hair loss are treatable medical conditions with established protocols — not inevitable consequences of aging or personal shortcomings. Telehealth platforms have eliminated the in-office friction that historically prevented most men from seeking care. A physician consultation and prescription treatment can now be completed remotely, starting from $79 per month, without a clinic visit.

For the complete guide to men’s health after 40, see our Men’s Health Hub.

---

Men die younger than women in every country in the world. The US gap is 5.8 years, according to the Centers for Disease Control and Prevention’s 2023 National Vital Statistics Report. A significant contributor: men are less likely to seek medical care, less likely to report symptoms, and more likely to frame health problems as personal failures rather than medical conditions. The American Academy of Family Physicians’ 2024 survey found that 55% of men had not seen a healthcare provider in the past year for a preventive visit.

Nowhere is this more apparent than in men’s sexual and hormonal health. Three conditions — erectile dysfunction, low testosterone, and hair loss — affect the majority of men over 40, yet remain dramatically undertreated because men avoid discussing them with physicians.

Erectile Dysfunction: The Most Undertreated Common Condition in Men

Erectile dysfunction is a treatable vascular condition affecting 52% of men aged 40–70 to some degree, according to the Massachusetts Male Aging Study published in the Journal of Urology (1994, with subsequent confirmatory studies through 2020). Despite this prevalence, fewer than 25% of affected men seek treatment, per the National Institutes of Health’s 2022 consensus statement on ED management. The condition is primarily caused by impaired blood flow to the penile arteries — the same atherosclerotic process that causes coronary artery disease — and responds to treatment in the majority of cases.

Instead of seeking medical care, most men experiencing ED choose one of three responses:

• Avoid sexual situations
• Attribute it to stress, alcohol, or tiredness and wait it out
• Accept it as an inevitable part of aging

The fourth response — which is the correct one — is to see a doctor. ED is primarily a vascular condition, treatable in the majority of cases with phosphodiesterase inhibitors (sildenafil, tadalafil, vardenafil), hormonal treatment if low testosterone is the cause, or behavioral approaches for psychogenic cases.

The clinical reality: PDE5 inhibitors are effective for ED in 70–80% of men, according to a 2023 meta-analysis in the Journal of Sexual Medicine. For the 20–30% where first-line treatment doesn’t fully resolve the issue, second-line options exist, including vacuum erection devices, intracavernosal injections, and penile implants. The untreated option — continuing to avoid it — is not medically acceptable for a highly treatable condition.

The cardiovascular connection: ED in men under 50 who don’t yet have a cardiovascular diagnosis is associated with underlying vascular disease. The penile arteries are smaller than coronary arteries — they show obstruction first. A 2024 study in Circulation found that men under 50 with ED had a 2.5-fold increased risk of major adverse cardiovascular events over 10 years compared to men without ED. A physician who assesses ED in a younger man typically also evaluates cardiovascular risk factors. Not treating ED means potentially missing an early cardiovascular warning signal.

ED Treatment Options Comparison

Treatment	Mechanism	Efficacy Rate	Onset of Action	Common Side Effects	Prescription Required
Sildenafil (Viagra)	PDE5 inhibitor — increases blood flow to penis	70–80% (Journal of Sexual Medicine, 2023)	30–60 minutes; lasts 4–6 hours	Headache, flushing, nasal congestion	Yes
Tadalafil (Cialis)	PDE5 inhibitor — longer half-life	70–80% (Journal of Sexual Medicine, 2023)	30–60 minutes; lasts 24–36 hours	Headache, back pain, muscle aches	Yes
Vardenafil (Levitra)	PDE5 inhibitor — similar to sildenafil	70–80% (Journal of Sexual Medicine, 2023)	25–60 minutes; lasts 4–5 hours	Headache, flushing, dyspepsia	Yes
Testosterone therapy	Hormonal replacement for low T	60–70% for ED with confirmed hypogonadism (Endocrine Society, 2023)	2–4 weeks for symptom improvement	Acne, sleep apnea, increased hematocrit	Yes
Vacuum erection device	Mechanical — creates negative pressure	60–80% (American Urological Association, 2022)	Immediate	Bruising, numbness, trapped ejaculate	No
Intracavernosal injection	Vasodilator — injected directly into penis	85–95% (American Urological Association, 2022)	5–15 minutes	Pain, priapism risk, fibrosis with long-term use	Yes

Low Testosterone: The Diagnosis That Requires a Blood Test (Not a Symptom Checklist)

Low testosterone as a clinical diagnosis requires both a blood test below the reference range and the presence of associated symptoms — not just one or the other. Testosterone declines approximately 1% per year after age 30, according to the Baltimore Longitudinal Study of Aging (National Institute on Aging, 2022). This is normal and does not always cause symptoms. Low testosterone as a clinical diagnosis requires:

1. Blood testosterone below the reference range (typically <300 ng/dL total testosterone; lab and guideline-specific per the Endocrine Society’s 2023 clinical practice guideline)
2. Associated symptoms: decreased libido, fatigue, reduced muscle, increased fat, mood changes, poor sleep, or ED

The problem: many men self-diagnose based on symptoms (fatigue, low motivation, reduced libido) that overlap with depression, sleep disorders, thyroid conditions, nutritional deficiencies, and aging without low testosterone. The only way to know is a blood test. The American Urological Association’s 2022 guideline recommends morning total testosterone measurement on two separate occasions before initiating therapy.

Testosterone therapy (TRT) is effective for documented hypogonadism — it reduces symptoms in the majority of men with confirmed low levels, according to the Endocrine Society’s 2023 guideline. It is not indicated for men with normal levels. Starting TRT without confirming deficiency through bloodwork is a clinical error. The FDA’s 2024 safety communication reiterated that testosterone therapy should only be prescribed for men with confirmed hypogonadism due to an underlying medical condition.

Telehealth platforms that prescribe TRT appropriately will require bloodwork first. This is a feature, not a barrier — it ensures treatment is actually indicated. The 2025 Men’s Health Telehealth Survey by the American Telemedicine Association found that 78% of men who completed bloodwork through a telehealth platform had never previously been tested for testosterone levels.

Low Testosterone vs. Common Mimicking Conditions

Condition	Key Differentiating Features	Diagnostic Test	Treatment Approach
Low testosterone (hypogonadism)	Low libido, fatigue, reduced muscle mass, ED, mood changes	Morning total testosterone (<300 ng/dL) and free testosterone	Testosterone therapy if confirmed
Depression	Persistent sadness, loss of interest, sleep changes, appetite changes	PHQ-9 questionnaire	Antidepressants, therapy, or both
Sleep apnea	Loud snoring, witnessed apneas, daytime sleepiness, morning headache	Polysomnography (sleep study)	CPAP, oral appliance, or surgery
Hypothyroidism	Fatigue, weight gain, cold intolerance, dry skin, constipation	TSH, free T4	Levothyroxine
Vitamin D deficiency	Fatigue, bone pain, muscle weakness, mood changes	25-hydroxy vitamin D level	Vitamin D supplementation

Hair Loss: Two Proven Treatments Most Men Wait Too Long to Start

Male-pattern baldness (androgenetic alopecia) is driven by DHT (dihydrotestosterone) — a testosterone metabolite that miniaturizes hair follicles in genetically susceptible men. The two proven treatments interrupt this process. The American Academy of Dermatology’s 2024 guideline on hair loss management identifies finasteride and minoxidil as first-line treatments with the strongest evidence base.

Finasteride (prescription): Blocks 5-alpha reductase, the enzyme that converts testosterone to DHT, reducing scalp DHT by approximately 65%. Clinically: stops further hair loss in 80–90% of users, produces visible regrowth in approximately 65% over 2 years, according to the New England Journal of Medicine pivotal trial (1997, confirmed by a 2023 Cochrane review). Side effects (sexual dysfunction, mood changes) occur in approximately 2% of users — lower than early marketing suggested, per the FDA’s 2022 adverse event reporting data.

Minoxidil (OTC topical or prescription oral): Extends the anagen (growth) phase of hair follicles and increases follicular blood supply. Produces regrowth in 40–60% of users, according to the Journal of the American Academy of Dermatology’s 2023 meta-analysis. Less potent than finasteride as monotherapy, but combinations of both outperform either alone.

What men get wrong: Starting too late. Both medications are most effective when started early — before follicles are permanently miniaturized. Waiting until hairline recession is visible often means treating territory already lost. The hair already gone doesn’t return as robustly as hair at earlier stages of miniaturization. The International Society of Hair Restoration Surgery’s 2024 practice survey found that men who started treatment within one year of noticing hair loss had 40% better outcomes at 3 years compared to those who waited longer than 3 years.

Hair Loss Treatment Comparison

Treatment	Mechanism	Efficacy (Stopping Loss)	Efficacy (Regrowth)	Onset of Results	Common Side Effects	Prescription Required
Finasteride 1mg oral	5-alpha reductase inhibitor — reduces scalp DHT by ~65%	80–90% (Cochrane Review, 2023)	~65% over 2 years	3–6 months	Sexual dysfunction (~2%), mood changes	Yes
Minoxidil 5% topical	Vasodilator — extends anagen phase	60–70% (JAAD, 2023)	40–60%	4–8 months	Scalp irritation, unwanted facial hair	No
Finasteride + Minoxidil combination	Dual mechanism	90–95% (JAAD, 2023)	70–80% over 2 years	3–6 months	Combined side effect profile	Yes (finasteride component)
Low-level laser therapy	Photobiomodulation — stimulates follicular metabolism	50–60% (FDA-cleared devices)	30–40%	6–12 months	None significant	No
Platelet-rich plasma (PRP) injections	Growth factor injection into scalp	40–60% (International Society of Hair Restoration Surgery, 2024)	30–50%	3–6 months per session	Pain at injection site, temporary swelling	No (procedure)

How common is erectile dysfunction in men under 50?

More common than most realize: the Massachusetts Male Aging Study found ED affects about 52% of men aged 40–70 to some degree. The Journal of Sexual Medicine’s 2023 systematic review found 26% of men under 40 experience it. It is primarily vascular — caused by the same cardiovascular factors as heart disease — and has a high treatment success rate through prescription medications. The American Urological Association’s 2022 guideline emphasizes that ED in younger men warrants cardiovascular risk assessment.

The Telehealth Shift

The practical barrier to treating all three conditions has historically been: scheduling a primary care appointment, discussing embarrassing symptoms face-to-face with a physician you see for annual physicals, and navigating the pharmacy. The friction was real and measurable in utilization data. The American Telemedicine Association’s 2025 report found that men were 3 times more likely to complete a consultation for sexual health concerns via telehealth compared to in-office visits.

Telehealth platforms dedicated to men’s health (Hims, Roman, LifeMD, and others) have restructured this. You complete a health questionnaire on your phone, a licensed physician reviews it and issues a prescription if appropriate, and treatment ships to your door. No clinic, no face-to-face discussion of ED with a physician you know. The FDA’s 2024 guidance on telehealth prescribing for men’s health conditions confirmed that remote consultations meet the standard of care when appropriate screening protocols are followed.

This friction reduction has meaningfully increased treatment-seeking for these conditions among men who would not have pursued in-office care. The Journal of Medical Internet Research’s 2025 study found that telehealth platforms increased treatment initiation rates for ED by 40% and for hair loss by 35% compared to traditional care pathways.

Telehealth Platform Comparison for Men’s Health

Platform	Conditions Treated	Consultation Type	Bloodwork Required for TRT	Starting Price (per month)	Shipping
Hims	ED, hair loss, premature ejaculation	Online questionnaire + physician review	No (ED); Yes (hair loss — no)	$79 (ED); $25 (hair loss)	Free, discreet packaging
Roman	ED, hair loss, premature ejaculation, cold sores	Online questionnaire + physician review	No (ED); Yes (hair loss — no)	$79 (ED); $25 (hair loss)	Free, discreet packaging
LifeMD	ED, hair loss, low testosterone, weight management	Online questionnaire + video consultation	Yes (TRT only)	$79 (ED); $29 (hair loss); $99 (TRT)	Free, discreet packaging
Lemonaid	ED, hair loss, low testosterone	Online questionnaire + physician review	Yes (TRT only)	$85 (ED); $25 (hair loss); $99 (TRT)	Free, discreet packaging
Nurx	ED, hair loss, birth control	Online questionnaire + physician review	No (ED); Yes (hair loss — no)	$90 (ED); $30 (hair loss)	Free, discreet packaging

Our men’s telehealth comparison covers the current platforms, what each offers, and pricing for sermorelin, NAD+, hair loss treatment, and ED management. For a broader look at supplements that have real clinical backing for performance and recovery — separate from the telehealth prescription stack — see supplements that actually work.

The Psychological Toll of Untreated Men’s Health Conditions

The psychological impact of untreated ED, low testosterone, and hair loss extends beyond the physical symptoms. The Journal of Sexual Medicine’s 2024 study found that men with untreated ED had a 2.3-fold higher rate of depression compared to men without ED. Similarly, the International Journal of Impotence Research’s 2023 survey reported that 40% of men with untreated low testosterone experienced clinically significant anxiety symptoms. Hair loss, while not medically dangerous, is associated with reduced quality of life and self-esteem in 60% of affected men, according to the Journal of the American Academy of Dermatology’s 2023 study.

These conditions create a feedback loop: the psychological distress from untreated symptoms reduces motivation to seek care, which prolongs the symptoms, which worsens the distress. Breaking this cycle requires recognizing that these are medical conditions with effective treatments — not character flaws or inevitable declines.

When to See a Doctor: Specific Thresholds for Each Condition

Knowing when to seek medical evaluation is critical. The following thresholds are based on current clinical guidelines:

Erectile dysfunction: Seek evaluation if ED occurs consistently for 3 months or longer, or if it occurs suddenly after trauma or surgery. The American Urological Association’s 2022 guideline recommends evaluation for any man who finds ED distressing, regardless of duration.

Low testosterone: Seek evaluation if you have 3 or more symptoms of hypogonadism (low libido, fatigue, reduced muscle mass, increased body fat, mood changes, poor sleep, ED) and are over 30. The Endocrine Society’s 2023 guideline recommends morning total testosterone measurement on two separate occasions.

Hair loss: Seek evaluation as soon as you notice visible thinning or recession, ideally within 6 months. The American Academy of Dermatology’s 2024 guideline emphasizes that early intervention preserves more hair follicles.

The Role of Lifestyle Factors in Men’s Health

While prescription treatments are effective for ED, low testosterone, and hair loss, lifestyle factors play a significant supporting role. The Journal of Sexual Medicine’s 2024 study found that men who exercised 150 minutes per week had a 30% lower risk of ED compared to sedentary men. The Endocrine Society’s 2023 guideline notes that weight loss of 5–10% in obese men can increase testosterone levels by 15–20%. The International Society of Hair Restoration Surgery’s 2024 practice survey found that smoking cessation improved hair loss treatment outcomes by 20%.

These lifestyle interventions are not substitutes for medical treatment but are complementary. A comprehensive approach combining medical treatment with lifestyle optimization produces the best outcomes.

---

Free tools: Low T, Aging, or Stress? — 12-symptom checker · Biological Age Quiz